Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)
Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Clinicaltrials.gov identifier:NCT06395519
Study Contact Information:
Name: 858 Therapeutics, Inc.
Phone Number: (858) 987-8380
Email: [email protected]
Or
Hira Zain – [email protected]
Natalie Velez- [email protected]
About the Study
Researchers are studying whether the ETX-19477 is a safe and effective treatment option for people with a mutation who have been diagnosed with or advanced breast, colorectal, endometrial, ovarian or pancreatic cancer. ETX-19477 is a type of drug known as a PARG inhibitor. It works by interfering with cancer cells' ability to repair damage to their . Researchers hope this may slow tumor growth or cause cancer cells to die.The goal of this study is to find the safest and most effective dose of ETX-19477 for treating or advanced cancers.
This Study is Open To:
People may be eligible if all of the following apply:
- They are age 18 or older.
- They have been diagnosed with advanced or breast, colorectal, endometrial, ovarian or pancreatic cancer.
- They have a mutation.
- Their cancer has come back or gotten worse after standard treatment or they cannot tolerate available treatments.
- Their cancer can be measured using imaging or other tests.
- They have a life expectancy of at least 3 months.
Visit Clinicaltrials.gov for the full eligibility listing.
This Study is NOT Open To:
People may not be eligible if they:
- Have untreated or worsening cancer that has spread to the brain or spinal fluid. People whose brain metastases have been treated and are stable may still qualify.
- Have significant heart problems or uncontrolled heart disease.
- Have an active serious infection, such as uncontrolled hepatitis B, hepatitis C, tuberculosis, or another significant infection.
- Have serious liver, kidney, gastrointestinal, or pancreatic disease that could affect safety or the body's ability to absorb the study drug.
- Have received radiation therapy too recently before starting the study.
- Are taking certain medications that may interact with ETX-19477 or affect how the body processes medications.
- Are receiving another investigational treatment or recently participated in another clinical trial.
- Have another cancer that required treatment within the past two years, with some exceptions for certain cancers.
Visit Clinicaltrials.gov for the full eligibility listing.
What the Study Involves
There is one arm to this study.
- All people enrolled in this study will receive the study drug.
- Participants will take ETX-19477 by mouth once daily.
- Participants will stay on this treatment until their cancer gets worse or they have side effects that require stopping the medication.
Study Contact Information:
Name: 858 Therapeutics, Inc.
Phone Number: (858) 987-8380
Email: [email protected]
Or
Hira Zain – [email protected]
Natalie Velez- [email protected]
Locations:
Arizona
City: Phoenix RECRUITING
Facility: Mayo Clinic
Contact Info:
Felipe Batalini, MD
Connecticut
City: New Haven RECRUITING
Facility: Yale University, Yale Cancer Center
Contact Info:
Michael Cecchini, MD
Florida
City: Jacksonville RECRUITING
Facility: Mayo Clinic
Contact Info:
Pooja Advani, MD
Illinois
City: Chicago RECRUITING
Facility: University of Chicago Medical Center
Contact Info:
Han Cun, MD
Massachusetts
City: Boston RECRUITING
Facility: Massachusetts General Hospital
Contact Info:
Richard T Penson, MD
Minnesota
City: Rochester RECRUITING
Facility: Mayo Clinic
Contact Info:
Siddhartha Yadav, MD
New York
City: New York RECRUITING
Facility: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
Contact Info:
Nancy Chan, MD
City: New York RECRUITING
Facility: Memorial Sloan Kettering Cancer Center
Contact Info:
Ezra Y Rosen, MD, PhD
Ohio
City: Columbus RECRUITING
Facility: Stefanie Spielman Comprehensive Breast Center
Contact Info:
Sagar Sardesai, MBBS
Pennsylvania
City: Philadelphia RECRUITING
Facility: Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
Contact Info:
Kevin Zarrabi, MD
Texas
City: Houston RECRUITING
Facility: MD Anderson Cancer Center
Contact Info:
Timothy A Yap, MD, PhD
Utah
City: Salt Lake City RECRUITING
Facility: START Center for Cancer Care - Mountain Region
Contact Info:
William B. McKean, Jr, MD
Virginia
City: Fairfax RECRUITING
Facility: Virginia Cancer Specialists
Contact Info:
Alexander I Spira, MD
Washington
City: Seattle RECRUITING
Facility: Fred Hutchinson Cancer Center
Contact Info:
Kalyan Banda, MD
Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Clinicaltrials.gov identifier:NCT06395519
Study Contact Information:
Name: 858 Therapeutics, Inc.
Phone Number: (858) 987-8380
Email: [email protected]
Or
Hira Zain – [email protected]
Natalie Velez- [email protected]